Life Science Investing Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
Life Science Investing Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
Life Science Investing Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
Apollo Files NI 43-101 Technical Report for the Calico Silver Project Updated Mineral Resource Estimate
